dc.contributor.author
Seifert, Georg
dc.contributor.author
Blakeslee, Sarah B.
dc.contributor.author
Calaminus, Gabriele
dc.contributor.author
Kandil, Farid I.
dc.contributor.author
Barth, Andrea
dc.contributor.author
Bernig, Toralf
dc.contributor.author
Classen, Carl Friedrich
dc.contributor.author
Corbacioglu, Selim
dc.contributor.author
Föll, Jürgen
dc.contributor.author
Gottschling, Sven
dc.contributor.author
Gruhn, Bernd
dc.contributor.author
Hoff-Heise, Claudia vom
dc.contributor.author
Lode, Holger N.
dc.contributor.author
Martin, David
dc.contributor.author
Nathrath, Michaela
dc.contributor.author
Neunhoeffer, Felix
dc.contributor.author
Pekrun, Arnulf
dc.contributor.author
Wulff, Beate
dc.contributor.author
Zuzak, Tycho
dc.contributor.author
Henze, Günter
dc.contributor.author
Längler, Alfred
dc.date.accessioned
2023-11-16T12:27:53Z
dc.date.available
2023-11-16T12:27:53Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/41565
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-41284
dc.description.abstract
Background: Integrative medicine is used frequently alongside chemotherapy treatment in pediatric oncology, but little is known about the influence on toxicity. This German, multi-center, open-label, randomized controlled trial assessed the effects of complementary treatments on toxicity related to intensive-phase chemotherapy treatment in children aged 1-18 with the primary outcome of the toxicity sum score. Secondary outcomes were chemotherapy-related toxicity, overall and event-free survival after 5 years in study patients.
Methods: Intervention and control were given standard chemotherapy according to malignancy & tumor type. The intervention arm was provided with anthroposophic supportive treatment (AST); given as anthroposophic base medication (AMP), as a base medication for all patients and additional on-demand treatment tailored to the intervention malignancy groups. The control was given no AMP. The toxicity sum score (TSS) was assessed using NCI-CTC scales.
Results: Data of 288 patients could be analyzed. Analysis did not reveal any statistically significant differences between the AST and the control group for the primary endpoint or the toxicity measures (secondary endpoints). Furthermore, groups did not differ significantly in the five-year overall and event-free survival follow up.
Discussion: In this trial findings showed that AST was able to be safely administered in a clinical setting, although no beneficial effects of AST between group toxicity scores, overall or event-free survival were shown.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Pediatric oncology trial
en
dc.subject
Anthroposophic medicine
en
dc.subject
Complementary cancer treatment
en
dc.subject
Randomized controlled trial
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
652
dcterms.bibliographicCitation.doi
10.1186/s12885-022-09703-0
dcterms.bibliographicCitation.journaltitle
BMC Cancer
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
22
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35698215
dcterms.isPartOf.eissn
1471-2407